Vertex Pharmaceuticals IncorporatedVRTX
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $12.22B, growing 10.1% year-over-year. TTM net income stood at $4.34B (538.7% growth). Quarterly EBITDA was $1.19B and operating income was $1.14B. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze VRTX growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters